Nucleic Acid-Based Vaccines
- Name
- Nucleic Acid-Based Vaccines
- Accession Number
- DBCAT005632
- Description
Vaccines formulated with nucleic acids specific for a target antigen. They are designed to induce antibody production against the target by host.
- Drugs
Drug Drug Description Moderna COVID-19 Vaccine An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. AstraZeneca COVID-19 Vaccine A two-dose replication-deficient adenovirus vector vaccine used to prevent COVID-19 caused by SARS-CoV-2. BNT162b1 SARS-CoV-2 Vaccine BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding... Tozinameran An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. Bizalimogene ralaplasmid Bizalimogene ralaplasmid is under investigation in clinical trial NCT03499795 (VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 And/or HPV-18 Related Anal or Anal/peri-anal, High Grade... Pidacmeran Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). BNT-162A1 BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). GI-6207 Not Annotated INO-4800 INO-4800 is a DNA vaccine containing the full sequence for the SARS-CoV-2 Spike (S) protein in development for immunization against COVID-19. Early in vitro studies using HEK-293T cells demonstrated that... CVnCoV Vaccine The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate... Rocakinogene sifuplasmid Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma (GBM)). Famtozinameran A component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineages BA.4 and BA.5. - Drugs & Drug Targets
Drug Target Type